A 8-mer Peptide of PGLYRP1/Tag7 Innate Immunity Protein Binds to TNFR1 Receptor and Inhibits TNFα-Induced Cytotoxic Effect and Inflammation
In the laboratory of molecular immunogenetics of cancer IGB RAS was demonstrated that the PGLYRP1/Tag7 innate immunity protein can be regarded as an inhibitor of TNFα cytotoxic activity via the interaction with its TNF receptor 1 (TNFR1). A C-terminal peptide fragment 17.1 of the molecule is responsible for this function. In this study was demonstrated that the minimal 8-mer region of this peptide (hereinafter – 17.1A) is capable to bind to TNFR1. As a result of such interaction, the cytotoxic signals induced by this receptor are blocked. In the Nursery for laboratory animals BIBCh RAS was demonstrates that this peptide an anti-inflammatory activity in vivo in the complete Freund’s adjuvant (CFA)-induced arthritis model in laboratory mice. Peptide 17.1A is capable to reduce periarticular inflammation, inhibit the development of synovitis and exhibit a protective effect on cartilage and bone tissues. The work was published in Frontiers in Immunology.
- Investigation of long-term fate of magnetic nanoparticles in mice
Scientists from Laboratory of molecular immunology of IBCh RAS performed first broad comprehensive study of factors which influence degradation rate of magnetic particles in mammals. For this aim magnetic spectral approach was developed, allowing non-invasive and quantitative measurement of magnetic particles in mice without influence of biogenic iron. Researchers studied the key factors that determine the degradation rate of nanoparticles: particle dose, size, zeta potential, type of polymer coating and internal architecture of nanoagents. The revealed deeper insights into the particle degradation in vivo may facilitate rational design of theranostic nanoparticles with predictable long-term fate in vivo. The work was published in ACS Nano.
- Conference "Pathological changes in the central nervous system. From model to the patient."
- FEBS Excellence Awards
Please note that applications for the new FEBS Excellence Awards are now open (from 1st June) and will close on 1st September. The online application system is here: https://fellowships.febs.org/ea_2021 and full details can be found on the FEBS website here: https://www.febs.org/our-activities/fellowships/febs-excellence-awards/. FEBS Excellence Awards are intended to support research projects in the molecular life sciences from early-career group leaders. They are granted over three years and amount to €100,000.